← Back to Clinical Trials
Recruiting NCT06649123

NCT06649123 Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06649123
Status Recruiting
Phase
Sponsor Origin Sciences
Condition Colorectal Cancer
Study Type OBSERVATIONAL
Enrollment 6,600 participants
Start Date 2024-11-01
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type OBSERVATIONAL
Interventions
Oricol Test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 6,600 participants in total. It began in 2024-11-01 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Development of a multiomics assay for use on OriColTM sampled rectal mucus for detection of cancer and significant polyps in symptomatic patients on the Colorectal Urgent Suspected Cancer pathway.

Eligibility Criteria

Inclusion Criteria: 1. Patients 18 years and over 2. Patients referred from primary care to the 'urgent suspected cancer' CRC pathway during the study period. 3. Patients who provide voluntary written informed consent to participate in the study. Exclusion Criteria: 1. Patients who are unable to undergo digital rectal examination (DRE). 2. Patients with peri-anal/anal symptoms that may limit DRE and proctoscopy examination and it would be clinically inappropriate to attempt to assess these patients. This may include conditions such as: * Patients who have undergone radiotherapy. * An acute or chronic anal fissure * Perianal haematoma * Acute thrombosed haemorrhoids * Post- operative anal stenosis * The presence of an obstructing anal/low rectal tumour or discomfort as a result of previous pelvic radiotherapy 3. Current pregnancy or suspicion of pregnancy.

Contact & Investigator

Central Contact

Jon Lacy-Colson, FRCS

✉ jon.lacy-colson@sath.nhs.uk

📞 +44(0)1743261000

Frequently Asked Questions

Who can join the NCT06649123 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06649123 currently recruiting?

Yes, NCT06649123 is actively recruiting participants. Contact the research team at jon.lacy-colson@sath.nhs.uk for enrollment information.

Where is the NCT06649123 trial being conducted?

This trial is being conducted at Telford, United Kingdom.

Who is sponsoring the NCT06649123 clinical trial?

NCT06649123 is sponsored by Origin Sciences. The trial plans to enroll 6,600 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology